Sevoflurane Inhibits Phorbol-Myristate-Acetate-induced Activator Protein-1 Activation in Human T Lymphocytes in Vitro: Potential Role of the p38-Stress Kinase Pathway
Loop, Torsten M.D.*; Scheiermann, Patrick†; Doviakue, David†; Musshoff, Frank Ph.D.‡; Humar, Matjaz Ph.D.§; Roesslein, Martin M.D.∥; Hoetzel, Alexander M.D.∥; Schmidt, Rene M.D.∥; Madea, Burkhard M.D.#; Geiger, Klaus K. M.D.**; Pahl, Heike L. Ph.D.††; Pannen, Benedikt H. J. M.D.‡‡
Background: Modulation of immune defense mechanisms by volatile anesthetics during general anesthesia may compromise postoperative immune competence and healing reactions and affect the infection rate and the rate of tumor metastases disseminated during surgery. Several mechanisms have been suggested to account for these effects. The current study was undertaken to examine the molecular mechanisms underlying these observations.
Methods: Effects of sevoflurane, isoflurane, and desflurane were studied in vitro in primary human CD3+ T-lymphocytes. DNA-binding activity of the transcription factor activator protein-1 (AP-1) was assessed using an electrophoretic mobility shift assay. Phorbol-myristate-acetate-dependent effects of sevoflurane on the phosphorylation of the mitogen-activated protein kinases were studied using Western blots, the trans-activating potency of AP-1 was determined using reporter gene assays, and the cytokine release was measured using enzyme-linked immunosorbent assays.
Results: Sevoflurane inhibited activation of the transcription factor AP-1. This effect was specific, as the activity of nuclear factor κB, nuclear factor of activated T cells, and specific protein-1 was not altered and several other volatile anesthetics studied did not affect AP-1 activation. Sevoflurane-mediated suppression of AP-1 could be observed in primary CD3+ lymphocytes from healthy volunteers, was time-dependent and concentration-dependent, and occurred at concentrations that are clinically achieved. It resulted in an inhibition of AP-1-driven reporter gene activity and of the expression of the AP-1 target gene interleukin-3. Suppression of AP-1 was associated with altered phosphorylation of p38 mitogen-activated protein kinases.
Conclusion: The data demonstrate that sevoflurane is a specific inhibitor of AP-1 and may thus provide a molecular mechanism for the antiinflammatory effects associated with sevoflurane administration.
GENERAL anesthesia can modulate immune defense mechanisms within the postoperative period.1
In particular, inhaled anesthetics contribute to postoperative immunosuppression, especially when applied in higher concentrations or doses or for longer periods of time.2,3
For example, two studies have demonstrated peripheral lymphocytopenia after inhalation anesthesia with halothane and nitrous oxide in patients undergoing elective hysterectomy.4,5
Giraud et al.
recently reported that halothane >1 Vol.%, delivered by mechanical ventilation, abated the early lipopolysaccharide-induced lung inflammation in the rat.6
Similarly, isoflurane pretreatment prevented the increase in tumor necrosis factor α associated with lipopolysaccharide-induced inflammation in rats.4,7–12
Previous studies have demonstrated that the total number of circulating neutrophils decreased during anesthetic exposure, whereas the number of lymphocytes increased.13,14
In contrast to the well documented clinical effects of inhaled anesthetics,1
the precise molecular mechanism of their immunosuppressive action remains to be identified. The following in vitro
studies have provided evidence that volatile anesthetics may alter the innate immune response. Halothane, enflurane, and sevoflurane inhibited the respiratory burst. Likewise, sevoflurane, isoflurane, and enflurane inhibit interleukin-1β and tumor necrosis factor α release as well as chemotaxis in human mononuclear cells and neutrophil adhesion to endothelial cells.15–19
However, exposure of interleukin-1β-stimulated alveolar type II cells to halothane, enflurane, and isoflurane reversibly decreased interleukin-6, macrophage inflammatory protein-2, and monocyte chemoattractant protein-1 concentrations in cell culture supernatants.20
Much less is known about the effect of inhalation anesthetics on the function of lymphocytes. The CD3+
cell population encompasses all known T cell populations, including CD4+
, and Th1 or Th2. We chose T cells in our model because they play a crucial role in the defense against nosocomial infections.21
Previous studies have demonstrated that halothane inhibits phytohemagglutinin-induced RNA and protein synthesis in human lymphocytes. This anesthetic also induces apoptosis, which may be mediated through the suppression of interleukin-2 receptor expression.22–24
The latter finding suggests that anesthetics could exert their immunosuppressive effects in part by inhibiting the transcription factor function of immune cells. This hypothesis is supported by the observation that thiopental suppresses induction of the nuclear factor κB (NF-κB) in human T lymphocytes.25
We therefore investigated whether volatile anesthetics likewise interfere with the activation of the transcription factor activator protein-1 (AP-1), a central transcriptional regulator of the immune and stress response in activated T cells.
AP-1 is an immediate early transcription factor that is involved in the regulation of cellular proliferation, transformation, differentiation, and the death of immune cells.26
AP-1 activity is induced by a wide range of physiologic stimuli and environmental insults and is composed of homodimers or heterodimers of the Jun family (c-Jun, JunD, and JunB) or of Jun heterodimers with any of the Fos family (c-Fos, FosB, Fra1, and Fra2) (fig. 1
). AP-1 proteins are targets of the mitogen-activated protein (MAP) kinase cascade.27
The MAP kinases are a family of serine-threonine protein kinases, of which four distinct subgroups have been described: 1) extracellular signal-regulated kinases (ERKs), 2) c-jun N-terminal or stress activated protein kinases (JNK/SAPK), 3) ERK5/big MAP kinase 1 (BMK1), and 4) the p38 group of protein kinases (fig. 1
). Five isoforms of p38 kinases have been identified in mammalian cells. These proteins, termed p38α, p38β, p38γ/SAPK3, p38δ/SAPK4, and p38–2, are similar in size, show about 60–75% sequence homology, and are activated by tumor necrosis factor α, interleukin-1, ultraviolet irradiation, and hyperosmolar medium.28
The α- and β-isoforms of p38 kinases are inhibited by a novel class of antiinflammatory drugs that block the access of adenosine triphosphate to the catalytic site of the kinase.29
In contrast, the γ and δ isoforms of p38 are insensitive to these pyridinyl-imidazole inhibitors.30
It was the aim of this study to examine whether sevoflurane, desflurane, or isoflurane interfere with the activation of the transcription factor AP-1 in primary human T lymphocytes and, if so, whether they target the upstream signal transduction pathway.
Materials and Methods
The following anesthetics and substances were used: sevoflurane, isoflurane (Abbott, Wiesbaden, Germany), and desflurane (Baxter, Unterschleiβheim, Germany). All other reagents were purchased from Sigma (Deisenhofen, Germany) unless otherwise specified.
Isolation of CD3+ T lymphocytes
Peripheral blood mononuclear cells were isolated from buffy coats that had been obtained from healthy donors using density centrifugation on Ficoll-Hypaque® (Amersham-Pharmacia, Freiburg, Germany) according to manufacturer recommendations. The cells were microscopically analyzed and counted in a Neubauer chamber. For the isolation of CD3+ T lymphocytes, peripheral blood mononuclear cells (3–4 × 108) were incubated for 15 min on ice with anti CD3-antibodies conjugated to magnetic beats (Miltenyi Biotech, Bergisch-Gladbach, Germany). Separation of CD3+ cells was performed using an L/S column (Miltenyi Biotech, Bergisch-Gladbach, Germany) and confirmed by fluorescence associated cell sorting (>92% purity). For electrophoretic mobility shift assays (EMSAs) > 2 × 106 T lymphocytes were analyzed per sample.
Jurkat T cells (ACC 282, DSMZ, Braunschweig, Germany) and primary human T lymphocytes isolated as described above, were maintained in Roswell Park Memorial Institute medium 1640 supplemented with 10% fetal calf serum, 1% glutamine, and 50 mg/ml penicillin and streptomycin (all from Gibco-BRL, Karlsruhe, Germany), and were grown in a humidified atmosphere containing 5% CO2 at 37°C.
Exposure to Volatile Anesthetics and Experimental Protocol
Jurkat T cells or primary CD3+ T lymphocytes were exposed to either air or volatile anesthetic/air mixture using a 12 l airtight glass chamber. The chamber atmosphere was kept continuously saturated with water at 37°C. Gas was prepared using a gas mixing unit by directing a 95% air/5% CO2 mixture at 6 l/min through calibrated vaporizers (Draeger, Lübeck, Germany) that were placed at the entrance of the chamber. In preliminary experiments, we observed that over an 48 h period the different culture conditions used in our experiments did not influence AP-1 activation in cells; the DNA binding activity was similar in a standard incubator and in the sealed chamber flushed with a 95% air/5% CO2 mixture. Volatile anesthetic concentrations were monitored at the chamber exit port using a halogen monitor (PM 8050; Dräger, Lübeck, Germany). Concentrations of the inhalation anesthetics dissolved in the cell culture medium were measured by a fully automated solid-phase microextraction procedure followed by gas chromatography and mass spectrometry (CTC Combi PAL autosampler, Agilent model 6890 Series plus Gas Chromatograph with Agilent 5973 N Mass Selective Detector; Chromtech, Idstein, Germany). Using an external standard method, calibration curves were achieved for sevoflurane, desflurane, and isoflurane. Based on this method the following concentrations of volatile anesthetics were measured in the culture medium after 24 h of incubation with volatile anesthetics: sevoflurane (8 Vol.%) 982 ± 4 μmol/l, isoflurane (5 Vol.%) 755 ± 6 μmol/l, desflurane (18 Vol.%) 1799 ± 12 μmol/l.
For each exposure condition, a control sample was obtained simultaneously from T cells cultured in a standard 95% air/5% CO2 incubator without anesthetic exposure. At the end of each experiment, both supernatants and T cells were frozen immediately in liquid nitrogen and stored at −80°C until protein extraction.
To analyze the effects of volatile anesthetics on AP-1, NF-κB, nuclear factor of activated T cells (NFAT), and specific protein-1 (SP-1) activation, cells were treated with sevoflurane, isoflurane, or desflurane. Thirty minutes before harvesting, the cells were stimulated with phorbol-myristate-acetate (PMA; 15 ng/ml) and ionomycin (700 ng/ml), after which nuclear cell protein extracts were prepared and analyzed for the DNA binding activity by electrophoretic mobility shift assays (EMSA).
Electrophoretic Mobility Shift Assays
Cells were harvested by centrifugation and washed once in ice-cold phosphate-buffered saline, and nuclear cell extracts were prepared according to the procedure described.31
Briefly, cells were incubated for 15 min at 4°C in 400 μl extraction buffer (10 mm HEPES (pH 7.9), 10 mm KCL, 0.1 mm EDTA, 0.1 mm EGTA, and 2.5 μl Nonidet P40). Pellets were solubilized in suspension buffer (20 mm HEPES (pH 7.9), 0.4 M NaCl, 1 mm EDTA, 1 mm EGTA, and 1 mm dithiothreitol). Supernatants were used for EMSA. Inhibitors of proteinases and phosphatases were added at the following concentrations to the extraction and suspension buffer: 10 μg/ml aprotinin, 25 μm leupeptin, 2 mm phenyl-methyl-sulfonyl-fluoride, 2 mm iodoacetamide, 10 mm sodium fluoride, and 10 mm sodium pyrophosphate. EMSAs were performed using a 32
P-labeled AP-1, NF-κB, or SP-1 oligonucleotide (25 ng/μl, Promega, Mannheim, Germany). EMSAs for NFAT were performed using the NFAT motif of the human granulocyte-monocyte colony stimulating factor enhancer region (5′-TTTCTCATGGAAAGATGACAT A-3′) as a probe. The kinase reaction consisted of 37 μl purified water, 1 μl AP-1 (or NF-κB, or SP-1) oligonucleotides, 5 μl kinase buffer, 5 μl γ- 32
P-d-adenosine triphosphate (Amersham International, Braunschweig, Germany), and 1.5 μl T4 kinase (PNK buffer and PNK T4 kinase; New England Biolabs, Schwalbach, Germany) and was incubated for 30 min at 37°C. The protein content of the cell lysates was determined using a Bradford-Assay system (Bio-Rad Laboratories, München, Germany), and equal amounts of protein (30 μg) were added to a 20 μl EMSA reaction mixture containing 20 μg bovine serum albumin, 2 μg poly(dI-dC) (Roche, Mannheim, Germany), 2 μl buffer D+ (20 mm HEPES, pH 7.9, 20% glycerol, 100 mm KCl, 0.5 mm EDTA, 0.25% Nonidet P-40, 2 mm dithiothreitol, 0.1% phenyl-methyl-sulfonyl-fluoride), 4 μl 5× Ficoll buffer (20% Ficoll 400, 100 mm HEPES, 300 mm KCl, 10 mm dithiothreitol, 0.1% phenyl-methyl-sulfonyl-fluoride), 1 μl 50 mm MgCl2
, 3 μl ddH2
O, and 1 μl AP-1 (or NFAT, NF-κB, or SP-1) 32
P-labeled oligonucleotide. These samples were incubated at room temperature for 30 min and then loaded on an acrylamide gel containing 60 ml ddH2
O, 10 ml 30% acrylamide, 3.8 ml 10× Tris-borate-EDTA buffer (900 mm TRIS-HCl, 900 mm boric acid, 20 mm EDTA [pH 8.0]), 400 μl ammonium persulfate, and 40 μl tetramethylethylenediamine. After running the gel in 0.5× Tris-borate-EDTA running buffer, gels were vacuum dried (Gel dryer 543, Bio-Rad, Hercules, CA) for 30 min on a 3 mm chromatography filter (Whatman, Maidstone, England) and exposed to radiographic film (Kodak, Stuttgart, Germany). For the supershift assays, 2.5 μl of antibody were added to the reaction simultaneously with the protein and incubated as described. Antic-jun, antic-jun (AP-1), anti-JunB, anti-JunD, antic-fos, anti-Fra1 and -Fra2, anti-FosB and anti-RelB antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Transfections and Luciferase Assays
Jurkat cells were plated 12–16 h before transfection at a density of 3 × 105 cells per well in a six-well plate. Cells were transiently transfected with a luciferase reporter gene construct (pAP1(PMA)TA-Luc vector, Clontech, Palo Alto, CA). Transfections were performed using the superfect reagent (Qiagen, Hilden, Germany) according to manufacturer descriptions. To exclude the possibility of differences in transfection efficiency, all cells were pooled at 6 h after transfection, gently mixed, and than equally distributed into individual wells for all further determinations. The experiment was repeated six times. Cells were pretreated with sevoflurane or desflurane for 1 h before stimulation with PMA and ionomycin (15/700 ng/ml) and harvested in situ after 23 h using a commercial lysis buffer and luciferase assay system (Promega, Mannheim, Germany). Luciferase activity was determined using a microplate luminometer (Eg & G-Berthold, Bad Wilbach, Germany) measuring light emission over an interval of 30 s. The results are expressed in arbitrary light units as percentage of the respective positive control.
Cell culture supernatants were analyzed for interleukin-3 (IL-3) 23 h after stimulation with PMA and ionomycin (15/700 ng/ml). Cells were pretreated with sevoflurane (8 Vol.%) for 1 h before stimulation. Measurements were performed using enzyme-linked immunosorbent assay kits purchased from R&D Systems (Minneapolis, MN) according to manufacturer instructions.
Western Blotting for p38, JNK1/2 and ERK1/2
Phosphorylation of p38, JNK1/2, and ERK1/2 was analyzed by Western blotting. To determine whether sevoflurane may interfere with the phosphorylation of these three MAP-kinases, CD3+ T cells were pretreated with sevoflurane (8 Vol.%) for 24 h and subsequently stimulated with PMA and ionomycin (15/700 ng/ml) for 15 min. Total cell extracts of CD3+ T cells (30 μg) were boiled in Laemmli sample buffer and subjected to 10% sodium dodecyl sulfate–polyacrylamide gel. Before transfer, gels were equilibrated for 15 min in cathode buffer, (25 mm Tris, 40 mm glycin, 10% methanol). Using a semidry blotting apparatus (Bio-Rad Laboratories, München, Germany), proteins were transferred at 0.8 mA/cm2 for 1 h onto Immobilon P membranes (Millipore Corp., Eschborn, Germany), preequilibrated in methanol (15 s), ddH2O (2 min each side), and anode buffer II (25 mm Tris/10% methanol). Equal loading and transfer were monitored by amido-black staining of the membranes. Nonspecific binding sites were blocked by immersing the membrane into blocking solution (10 mm Tris-HCl, pH 8.0, 150 mm NaCl, 0,1% Tween-20 [v/v]) containing 5% milk powder (Fluka, Buchs, Switzerland) for 1 h at room temperature. Membranes were washed in blocking solution and incubated in a 1:1000 dilution of anti-p38 (Cat. No. 9212), anti-JNK1/2 (Cat. No. 9252), anti-ERK1/2 (Cat. No. 9102) antibody, or antiphosphorylated-p38, -JNK1/2, -ERK1/2 (Cat. No. 9910; all Cell Signaling Technology Inc., Beverly, MA) in blocking solution plus 5% bovine serum albumin overnight at 4°C, followed by extensive washing with blocking solution. Bound antibody was decorated with goat-antirabbit/horseradish peroxidase conjugate (Amersham Pharmacia, Freiburg, Germany), diluted 1:2000 in blocking solution, for 30 min at room temperature. After washing four times (5 min each), the immunocomplexes were detected using ECL Western blotting reagents (Amersham-Pharmacia, Freiburg, Germany) according to manufacturer instructions. Exposure to Kodak XAR-5 films (Stuttgart, Germany) was performed for 15 s to 1 min.
Quantitative and Statistical Analysis
Differences in measured variables between the experimental conditions were assessed using one-way analysis of variance on ranks followed by a nonparametric Student-Newman-Keuls test for multiple comparisons. Results were considered statistically significant if P < 0.05. The tests were performed using the SigmaStat software package (Jandel Scientific, San Rafael, CA).
Effects of Sevoflurane on AP-1 Activation
Treatment of CD3+
T lymphocytes with PMA (15 ng/ml) and ionomycin (700 ng/ml) induced AP-1 DNA binding activity compared with untreated cells (fig. 2
, lanes 1 and 2). Induced AP-1 activation was inhibited by pretreatment of cells with sevoflurane (8 Vol.%) (fig. 2
, lane 3). In contrast, incubation of T cells with sevoflurane alone had no effect on the activation of AP-1 (fig. 2
, lane 4).
Concentration-dependent and Time-dependent Effects of Sevoflurane and AP-1 Activation
We evaluated whether the concentration and the exposure time to sevoflurane may affect the activation of AP-1 DNA binding. CD3+
T cells were incubated with different concentrations of sevoflurane (2, 4, 6, and 8 Vol.%) and stimulated with PMA and ionomycin. As shown in figure 3
, activation of AP-1 was inhibited after exposure to 2, 4, 6, and 8 Vol.% sevoflurane (fig. 3
, lanes 2, 5, 8, and 11 compared with lanes 3, 6, 9, and 12 respectively). AP-1 DNA binding activity was suppressed beginning at 12 h of sevoflurane exposure (fig. 4
, lanes 9 and 12).
Effects of Sevoflurane on SP-1 Activation
In order to determine whether sevoflurane specifically inhibits AP-1 activation or whether DNA binding of a immunologically nonrelevant transcription factor is also perturbed, we performed additional EMSAs using a DNA probe containing the consensus motif for the transcription factor SP-1. Treatment of CD3+
T cells with sevoflurane (8 Vol.%) with subsequent administration of PMA (15 ng/ml) and ionomycin (700 ng/ml) did not detectably affect DNA binding of SP-1 to its DNA probe (fig. 5
, lanes 2 and 3).
Effects of Sevoflurane on NF-κB and NFAT Activation
To determine whether sevoflurane specifically inhibits AP-1 activation or whether DNA binding of other immunologically relevant transcription factors is also perturbed, we performed additional EMSAs using a DNA probe containing the consensus motif for the transcription factors NF-κB and NFAT. Treatment of CD3+
T cells with sevoflurane (8 Vol.%) with or without subsequent administration of PMA and ionomycin did not affect DNA binding of NF-κB and NFAT to their respective DNA elements (fig. 6A and B
, lanes 1 to 4).
Effects of Desflurane and Isoflurane on AP-1 Activation
The results described above raised the question whether the suppression of AP-1 activation by sevoflurane is specific for this drug or a common biologic effect of other volatile anesthetic agents. Therefore, we tested whether desflurane or isoflurane, when applied at maximal concentrations, also affect the activation of AP-1. However, in contrast to the results obtained with sevoflurane, desflurane, and isoflurane did not inhibit AP-1 activation in CD3+
T lymphocytes (fig. 7A and B
, lanes 1 to 4).
Sevoflurane and AP-1-Driven Reporter Gene Activity
Sevoflurane potently inhibits AP-1 DNA binding in EMSAs (figs. 2–4
), raising the question whether this results in a comparable inhibition of AP-1-dependent gene expression. Therefore, Jurkat T cells were transiently transfected with a luciferase reporter gene driven by AP-1 binding sites preceding a minimal promoter (pAP1(PMA)TA-Luc). PMA/ionomycin stimulation resulted in a profound increase in reporter gene activity (fig. 8
). Desflurane and sevoflurane alone had no effect on the activation of the AP-1-driven promoter; likewise, the PMA/ionomycin-induced activation was unaffected by desflurane. In contrast, AP-1-dependent reporter gene activity was suppressed by sevoflurane (fig. 8
Effects of Sevoflurane on Expression of Interleukin-3
To determine whether inhibition of AP-1 transcriptional activity by sevoflurane in CD3+ T lymphocytes is associated with altered production of a target gene of AP-1, the effect of sevoflurane on IL-3 release was studied. In CD3+
T cells the release of IL-3 increased upon PMA and ionomycin stimulation (fig. 9
). Sevoflurane attenuated this increase in the production of IL-3 (fig. 9
Effects of Sevoflurane on MAP-Kinase Phosphorylation
The effect of sevoflurane on MAP-kinase phosphorylation was studied by using phospho-specific antibodies against p38, JNK1/2, and ERK1/2. Treatment of CD3+
T lymphocytes with PMA (15 ng/ml) and ionomycin (700 ng/ml) induced the phosphorylation of p38, JNK1/2, and ERK1/2 (fig. 10, A, B, C
, upper panel, lanes 1 and 2). Pretreatment of CD3+
T cells with sevoflurane (8 Vol.%) with subsequent administration of PMA and ionomycin did not affect the phosphorylation of JNK1/2 and ERK1/2 MAP-kinases (fig. 10, B, C
, upper panel, lane 3). However, after sevoflurane exposure, the PMA/ionomycin-induced phosphorylation of p38 was more pronounced than after PMA/ionomycin stimulation alone (fig. 10, A
, upper panel, lane 2 and 3). Furthermore, even in the absence of PMA/ionomycin exposure to sevoflurane (8 Vol. %) alone significantly increased the phosphorylation of p38, whereas JNK1/2 and ERK1/2 were not affected (fig. 10, A–C
, upper panel, lane 4). The total amount of p38, JNK1/2, and ERK1/2 was constant throughout each experiment (fig. 10, A–C
, lower panel, lanes 1–4).
Effects of p38-Inhibitiors on Sevoflurane-Suppressed AP-1 Activation
The transcription factor AP-1 can be activated by the different isoforms of the p38 MAP-kinases in a selective and opposite manner. Therefore, we wanted to assess AP-1 DNA binding activity after pretreatment with specific inhibitors of the p38α and p38β isoforms (SD203580 and SD202190 respectively, No. 19–134 and 19–135; Upstate Biotechnologies, Lake Placid, NY). As demonstrated previously, treatment of CD3+
T lymphocytes with PMA and ionomycin induced AP-1 DNA binding activity (fig. 11
, lanes 1 and 2), which was inhibited by pretreatment of cells with sevoflurane (8 Vol.%) (fig. 11
, lane 3). Preincubation of CD3+
T cells with either SD203580 or SD202190 before sevoflurane exposure reduced AP-1 induction on PMA and ionomycin stimulation more potently than sevoflurane alone (fig. 11
, lanes 4 and 5).
Protein Binding to the AP-1 Site Induced by PMA and Ionomycin
To determine which protein species binds to the AP-1 site induced by PMA and ionomycin, we performed supershift analysis using antibodies against different AP-1 subunits. These experiments indicated that the AP-1 complex induced by PMA/ionomycin is composed mainly of c-jun, JunB, JunD, c-Fos and FosB (fig. 12
, lanes 3 to 10).
Effect of Sevoflurane on Protein Binding to the AP-1 Site after Induction by PMA and Ionomycin
To determine which protein binding to the AP-1 site is inhibited by sevoflurane, we performed supershift analysis on extracts of cells pretreated with sevoflurane using the same antibodies described above. These experiments indicated that the treatment of cells with sevoflurane appeared to influence mainly JunD and Fra2 DNA binding most and affect c-jun, JunB and FosB to a lesser extent (fig. 13
, lanes 4 to 11).
Effect of Sevoflurane on Various Stimulators of AP-1 DNA Binding Activity
To consider the effect of other inducing agents that may stimulate AP-1 activity, we have exposed CD3+
T cells to CD3/CD28-beads, tumor necrosis factor α, and serum. AP-1 DNA binding activity was induced upon all stimuli (fig. 14
, lanes 2, 4, 6, and 8). Sevoflurane inhibited CD3/CD28-dependent (fig. 14
, lane 5) and tumor necrosis factor-induced (fig. 14
, lane 7; slight) AP-1 activity. In contrast, serum-induced AP-1 activation was unaffected by sevoflurane (fig. 14
, lane 9).
It has been recently recognized that general anesthetics may modulate and impair immune defense mechanisms.32–37
This is of particular importance because anesthetics are exclusively administered to patients undergoing surgical procedures who are therefore at particular risk of developing infections. Compromised immunity could affect the postoperative infection rate, healing reactions, and the rate and size of tumor metastases disseminated during surgery.1,3,13,38
However, evidence regarding immunomodulatory effects of volatile anesthetics is conflicting. This may result from differences in study designs as well as the inherent limitations of in vitro
models. Thus, it was the aim of the current study to identify the molecular mechanism by which sevoflurane, isoflurane, or desflurane may modulate the activation of various transcription factors in human T lymphocytes.
Our data demonstrate that the volatile anesthetic sevoflurane inhibits activation of the transcription factor AP-1 in isolated CD3+ T lymphocytes. The effect of sevoflurane had the following characteristics:
1) it appeared to be a specific pharmacological characteristic of sevoflurane, as it occurred in a dose-dependent and time-dependent manner and the other volatile anesthetics tested (isoflurane and desflurane) did not exert any inhibitory effect on AP-1 activation. In addition, DNA-binding activity of NF-κB, NFAT, and SP-1 in T cells was not affected by sevoflurane treatment;
2) it was associated with an inhibition of AP-1-driven reporter gene activity and of expression of the AP-1 target gene IL-3;
3) sevoflurane-mediated AP-1 inhibition is associated with the activation of p38;
4) in contrast, ERK and JNK activation is not involved; and
5) it may involve with the δ or γ isoform of p38 because sevoflurane-mediated inhibition of AP-1 activation was even more pronounced after treatment with inhibitors of the p38α and β isoforms. We thus propose that sevoflurane may exert its antiinflammatory and antiproliferative effects through inhibition of the activation of AP-1.
Several previously reported effects of volatile anesthetics on the regulation of immune cells could be explained by their inhibitory effect on AP-1. AP-1 acts as an environmental biosensor to various external stimuli.26
AP-1 proteins are key regulatory molecules that convert MAP kinase cascade signals into expression of specific target genes.27
In unstimulated T cells, AP-1 expression is low or undetectable. However, there is a rapid induction of AP-1 activity after T cell stimulation, which is mediated through the T cell/CD3+
receptor complex. Thus, it would be tempting to speculate that the inhibitory effect of volatile anesthetics alters T cell stimulation. Indeed, previous studies demonstrated that halothane inhibited PMA-induced transcription, RNA and protein synthesis in cultured human lymphocytes.22
Furthermore, in an inflammatory pain model, noxious stimulation-induced c-Fos protein expression in the spinal cord of the rat is suppressed after halothane-based or isoflurane-based general anesthesia.39,40
These results argue that volatile anesthetics can attenuate T cell activity. Likewise, the following changes have been observed after sevoflurane exposure: a reduced oxidative burst, a reduced number of human neutrophils, an attenuation of tumor necrosis factor α and interleukin-1β production in peripheral blood mononuclear cells in response to natural killer-sensitive tumor cells, and the reduction of the postischemic adhesion of polymorphonuclear leukocytes to human umbilical vein endothelial cells in vitro
All of these effects could be the result of AP-1 inhibition. Pretreatment with sevoflurane reduces neutrophil-endothelium interaction. This may contribute to the preconditioning effects of sevoflurane observed in vivo
during ischemia-reperfusion injury. In addition, variations in the total number and subsets of circulating T lymphocytes and decreased neutrophil respiratory burst observed during inhalational anesthesia would also be consistent with an inhibition of AP-1.4,42
In contrast, sevoflurane enhanced the binding of platelets to the surface of lymphocytes, neutrophils, and monocytes and increased the expression of P-selectin, an AP-1-regulated mediator of platelet-leukocyte adhesion, in platelets in vitro
The following lines of evidence suggest that the sevoflurane-mediated inhibition of AP-1 described here may be of clinical relevance. First, the suppressing effect of sevoflurane could be observed in human primary CD3+
T lymphocytes that had been obtained from healthy donors. Second, the inhibitory action occurred at in vitro
concentrations comparable to those attained in the plasma of people during administration of sevoflurane for general anesthesia.44,45
Concentrations of sevoflurane as low as 2 Vol.% caused a profound attenuation of the DNA-binding activity of AP-1 in T lymphocytes. Therefore, it is of particular interest that based on the medium/gas partition coefficients, concentrations obtained in the culture medium of our model were calculated to be ≈ 1.0 mm sevoflurane, which would be higher than the clinical dose.44,45
Finally, incubation of cells with sevoflurane caused a profound attenuation of IL-3 production, which plays a functional role in T cell growth, differentiation, and leukocyte adhesion.46–48
Likewise, beside IL-3, genes such as interleukin-2 and granulocyte-monocyte colony stimulating factor are under AP-1 control through the putative cis-acting AP-1 sites in their promoter and enhancer regions.49
Therefore, volatile anesthetic-induced apoptosis in lymphocytes could be explained in the same manner because withdrawal of interleukin-2, IL-3, or granulocyte-monocyte colony stimulating factor promotes cell death.23,50,51
Our observation raises the question by which underlying mechanism sevoflurane may inhibit the activation of AP-1. AP-1 activity is induced by a variety of environmental stress factors.26
These stimuli activate MAP kinase cascades that enhance AP-1 activity through converting phosphorylation of distinct substrates (fig. 1
). The MAP kinases consist of three main protein kinase families: the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs), and the p38 family of kinases (fig. 1
). Furthermore, the protein kinase C, cyclic-adenosine-monophosphate, and calcium pathways regulate c-fos expression, whereas protein kinase C and calcium are the main upstream modulators of c-jun, the most important transcriptional activator of the AP-1 menagerie of proteins.26
Protein kinase C is also an important initiator of the MAP kinase pathway.52
Previous studies indicated that volatile anesthetics activate protein kinase C and Ca2+
-calmodulin-dependent protein kinase II in various tissue preparations.53
In addition, it has been shown that isoflurane increased phosphorylated ERK1/2 in cultured smooth muscle cells.53
In this study, a dose-dependent increase in phosphorylation of ERK1/2 was initiated upstream by activation of Ca2+
-calmodulin-dependent protein kinase II and Ca2+
-independent protein kinase C. This raises the question whether volatile anesthetics may interfere with the signal transduction cascade leading to the activation of other MAP kinases. Indeed, ERK and JNK did not seem to be involved in the inhibition of AP-1 activity; sevoflurane exposure did not alter the phosphorylation of these MAP kinases. In contrast, appearance of immunoreactive phospho-p38 could be observed after sevoflurane exposure alone, even without stimulation by PMA. In addition, we observed an additive phosphorylation of p38 after sevoflurane incubation and subsequent stimulation with PMA and ionomycin. Enzymes in the p38 MAP kinase module are subject to phosphorylation and are generally activated by environmental stresses. The five p38 isoforms defined to date (p38α, p38β, p38γ, p38δ, and p38–2) vary in functional relevance based on their substrate specificity and in their affinity for the pyridinyl-inhibitors SB203580 and SB202190. These drugs are nearly equipotent against p38α and β but do not inhibit p38γ or p38δ.30,54
The latter p38 kinase isoforms have nearly 60% identity to p38α, but less is known about their physiologic function.28
Previous data indicate that the different p38 isoforms have opposite effects on AP-1-dependent transcription through differential regulation of c-Jun.55
Whereas the p38β isoform increases the activation of AP-1 transcriptional activity, p38γ/p38δ inhibits it by regulating the c-jun transcription.55
In our study, we were not able to definitively identify which p38 isoform was induced by sevoflurane. However, selective blockade of p38α/p38β by the inhibitors SB202190 and SB203580, which are inactive against p38δ/p38γ, increased the sevoflurane-mediated AP-1 inhibition. This was not reflected by the slight increase of PMA/ionomycin-induced p38 phosphorylation after sevoflurane exposure compared with stimulated T cells alone, which may have contributed to an increase in the phosphorylation of the p38γ/p38δ isoforms. Therefore, our data would be consistent with the assumption that sevoflurane may interfere with the p38δ isoform, which, in contrast to p38γ, exists in T cells and is not inhibited by these compounds.56
In conclusion, our data suggest that sevoflurane is a specific inhibitor of AP-1, which may exert its effect by interfering with the p38 MAP kinase cascade. Our data may provide a potential molecular mechanism for the immunomodulating effects associated with sevoflurane administration.
1. Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S: Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: Results from overview of randomised trials. BMJ 2000; 321:1–12
2. Peric M, Vranes Z, Marusic M: Immunological disturbances in anaesthetic personnel chronically exposed to high occupational concentrations of nitrous oxide and halothane. Anaesthesia 1991; 46:531–7
3. Salo M: Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36:201–20
4. Rem J, Brandt MR, Kehlet H: Prevention of postoperative lymphopenia and granulocytosis by epidural analgesia. Lancet 1980; 1:283–4
5. Oka M, Hirazawa K, Yamamoto K, Iizuka N, Hazama S, Suzuki T, Kobayashi N: Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. Ann Surg 1996; 223:434–40
6. Giraud O, Seince PF, Rolland C, Lecon-Malas V, Desmonts JM, Aubier M, Dehoux M: Halothane reduces the early lipopolysaccharide-induced lung inflammation in mechanically ventilated rats. Am J Respir Crit Care Med 2000; 162:2278–86
7. Plachinta RV, Hayes JK, Cerilli LA, Rich GF: Isoflurane pretreatment inhibits lipopolysaccharide-induced inflammation in rats. Anesthesiology 2003; 98:89–95
8. Kehlet H, Thomsen M, Kjaer M, Platz P: Postoperative depression of lymphocyte transformation response to microbial antigens. Br J Surg 1977; 64:890–3
9. Hansbrough JF, Bender EM, Zapata-Sirvent R, Anderson J: Altered helper and suppressor lymphocyte populations in surgical patients: A measure of postoperative immunosuppression. Am J Surg 1984; 148:303–7
10. Khan FA, Kamal RS, Mithani CH, Khurshid M: Effect of general anaesthesia and surgery on neutrophil function. Anaesthesia 1995; 50:769–75
11. Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA: Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 1996; 119:316–25
12. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR: Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999; 177:55–60
13. Morisaki H, Aoyama Y, Shimada M, Ochiai R, Takeda J: Leucocyte distribution during sevoflurane anaesthesia. Br J Anaesth 1998; 80:502–3
14. Wiesner G, Hoerauf K, Schroegendorfer K, Sobczynski P, Harth M, Ruediger HW: High-level, but not low-level, occupational exposure to inhaled anesthetics is associated with genotoxicity in the micronucleus assay. Anesth Analg 2001; 92:118–22
15. Frohlich D, Rothe G, Schwall B, Schmid P, Schmitz G, Taeger K, Hobbhahn J: Effects of volatile anaesthetics on human neutrophil oxidative response to the bacterial peptide FMLP. Br J Anaesth 1997; 78:718–23
16. Frohlich D, Rothe G, Schmitz G, Hansen E: Volatile anaesthetics induce changes in the expression of P-selectin and glycoprotein Ib on the surface of platelets in vitro. Eur J Anaesthesiol 1998; 15:641–8
17. Moudgil GC, Gordon J, Forrest JB: Comparative effects of volatile anaesthetic agents and nitrous oxide on human leucocyte chemotaxis in vitro. Can Anaesth Soc J 1984; 31:631–7
18. Mitsuhata H, Shimizu R, Yokoyama MM: Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol 1995; 17:529–34
19. Mobert J, Zahler S, Becker BF, Conzen PF: Inhibition of neutrophil activation by volatile anesthetics decreases adhesion to cultured human endothelial cells. Anesthesiology 1999; 90:1372–81
20. Giraud O, Molliex S, Rolland C, Lecon-Malas V, Desmonts JM, Aubier M, Dehoux M: Halogenated anesthetics reduce interleukin-1β-induced cytokine secretion by rat alveolar type II cells in primary culture. Anesthesiology 2003; 98:74–81
21. Slifka MK, Whitton JL: Clinical implications of dysregulated cytokine production. J Mol Med 2000; 78:74–80
22. Bruce DL: Halothane inhibition of RNA and protein synthesis of PHA-treated human lymphocytes. Anesthesiology 1975; 42:11–4
23. Matsuoka H, Kurosawa S, Horinouchi T, Kato M, Hashimoto Y: Inhalation anesthetics induce apoptosis in normal peripheral lymphocytes in vitro. Anesthesiology 2001; 95:1467–72
24. Hamra JG, Yaksh TL: Halothane inhibits T cell proliferation and interleukin-2 receptor expression in rats. Immunopharmacol Immunotoxicol 1996; 18:323–36
25. Loop T, Liu Z, Humar M, Hoetzel A, Benzing A, Pahl HL, Geiger KK, BH JP: Thiopental inhibits the activation of nuclear factor κB. Anesthesiology 2002; 96:1202–13
26. Foletta VC, Segal DH, Cohen DR: Transcriptional regulation in the immune system: All roads lead to AP-1. J Leukoc Biol 1998; 63:139–52
27. Ono K, Han J: The p38 signal transduction pathway: Activation and function. Cell Signal 2000; 12:1–13
28. Cowan KJ, Storey KB: Mitogen-activated protein kinases: New signaling pathways functioning in cellular responses to environmental stress. J Exp Biol 2003; 206:107–15
29. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997; 272:12116–21
30. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR: Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997; 235:533–8
31. Schneider R, Gander I, Muller U, Mertz R, Winnacker EL: A sensitive and rapid gel retention assay for nuclear factor I and other DNA-binding proteins in crude nuclear extracts. Nucleic Acids Res 1986; 14:1303–17
32. Brand JM, Kirchner H, Poppe C, Schmucker P: The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol 1997; 83:190–4
33. Galley HF, Webster NR: Effects of propofol and thiopentone on the immune response. Anaesthesia 1997; 52:921–3
34. Galley HF, DiMatteo MA, Webster NR: Immunomodulation by anaesthetic, sedative and analgesic agents: Does it matter? Intensive Care Med 2000; 26:267–74
35. Kotani N, Hashimoto H, Sessler DI, Kikuchi A, Suzuki A, Takahashi S, Muraoka M, Matsuki A: Intraoperative modulation of alveolar macrophage function during isoflurane and propofol anesthesia. Anesthesiology 1998; 89:1125–32
36. Kotani N, Hashimoto H, Sessler DI, Yasuda T, Ebina T, Muraoka M, Matsuki A: Expression of genes for proinflammatory cytokines in alveolar macrophages during propofol and isoflurane anesthesia. Anesth Analg 1999; 89:1250–6
37. Mattila-Vuori A, Salo M, Iisalo E: Immune response in infants undergoing application of cast: Comparison of halothane and balanced anesthesia. Can J Anaesth 1999; 46:1036–42
38. Moudgil GC, Singal DP: Halothane and isoflurane enhance melanoma tumour metastasis in mice. Can J Anaesth 1997; 44:90–4
39. Hagihira S, Taenaka N, Yoshiya I: Inhalation anesthetics suppress the expression of c-Fos protein evoked by noxious somatic stimulation in the deeper layer of the spinal cord in the rat. Brain Res 1997; 751:124–30
40. Jinks SL, Antognini JF, Martin JT, Jung S, Carstens E, Atherley R: Isoflurane, but not halothane, depresses c-fos expression in rat spinal cord at concentrations that suppress reflex movement after supramaximal noxious stimulation. Anesth Analg 2002; 95:1622–8
41. Kowalski C, Zahler S, Becker BF, Flaucher A, Conzen PF, Gerlach E, Peter K: Halothane, isoflurane, and sevoflurane reduce postischemic adhesion of neutrophils in the coronary system. Anesthesiology 1997; 86:188–95
42. Gasparoni A, Ciardelli L, De Amici D, Castellazzi AM, Autelli M, Bottino R, Polito E, Bartoli A, Rondini G, Chirico G: Effect of general and epidural anaesthesia on thyroid hormones and immunity in neonates. Paediatr Anaesth 2002; 12:59–64
43. Horn NA, de Rossi L, Robitzsch T, Hecker KE, Hutschenreuter G, Rossaint R: The effects of sevoflurane and desflurane in vitro on platelet-leukocyte adhesion in whole blood. Anaesthesia 2003; 58:312–9
44. Eckenhoff RG, Johansson JS: Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 1997; 49:343–67
45. Eckenhoff RG, Johansson JS: What are “relevant” concentrations? Anesthesiology 2001; 95:1537–9
46. Mathey-Prevot B, Andrews NC, Murphy HS, Kreissman SG, Nathan DG: Positive and negative elements regulate human interleukin 3 expression. Proc Natl Acad Sci U S A 1990; 87:5046–50
47. Shoemaker SG, Hromas R, Kaushansky K: Transcriptional regulation of interleukin 3 gene expression in T lymphocytes. Proc Natl Acad Sci U S A 1990; 87:9650–4
48. Martinez-Moczygemba M, Huston DP: Biology of common β-receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003; 112:653–65
49. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263–93
50. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA: Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13:1109–66
51. Thatte U, Dahanukar S: Apoptosis: Clinical relevance and pharmacological manipulation. Drugs 1997; 54:511–32
52. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ: Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998; 18:790–8
53. Zhong L, Su JY: Isoflurane activates PKC and Ca(2+) -calmodulin-dependent protein kinase II via MAP kinase signaling in cultured vascular smooth muscle cells. Anesthesiology 2002; 96:148–54
54. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J: Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J Biol Chem 1996; 271:17920–6
55. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, Chen G: p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun: The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 2003; 278:4831–9
56. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di Padova F, Ulevitch RJ, Han J: Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38δ. J Biol Chem 1997; 272:30122–8
This article has been cited 9 time(s).
Acta Anaesthesiologica ScandinavicaGene expression of pulmonary cytokines after sevoflurane or thiopentone anaesthesia in pigsActa Anaesthesiologica Scandinavica
Acta Anaesthesiologica ScandinavicaAnaesthesia for renal transplant surgeryActa Anaesthesiologica Scandinavica
Anesthesia and AnalgesiaSevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cellsAnesthesia and Analgesia
Journal of AnesthesiaAnesthetics, immune cells, and immune responsesJournal of Anesthesia
Archives of Neurology
The Common Inhalational Anesthetic Sevoflurane Induces Apoptosis and Increases beta-Amyloid Protein Levels
Archives of Neurology, 66(5):
Journal of NeuroinflammationSevoflurane reduces clinical disease in a mouse model of multiple sclerosisJournal of Neuroinflammation
European Journal of Anaesthesiology (EJA)Effects of different anaesthetic agents on immune cell functionin vitroEuropean Journal of Anaesthesiology (EJA)
© 2004 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.